A coalition of institutional investors is pushing Eli Lilly (LLY) to adopt a policy to disclose when executive pay is clawed back for misconduct. But the company is refusing to do so, even though more than a dozen large drug makers, wholesalers, and retailers have agreed to take such a step.
The rationale for the move, which was made in a shareholder proposal, is that Lilly faces substantial financial, legal, and reputational risks stemming from allegations that the company engaged in anti-competitive pricing over insulin. Specifically, the drug maker faces several lawsuits filed by various U.S. states as well as congressional investigations into allegations of price gouging.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
